Mariotto AB et al., 2011-01-19: Peer-reviewed projection linking SEER prevalence to SEER-Medicare costs: $124.57B in 2010 and $157.77B in 2020 if incidence, survival and costs stay constant, rising to $173B with 2% annual cost growth.
with associated costs of cancer care of 124.57 and 157.77 billion 2010 US dollars
Abstract, RESULTS
Mariotto AB et al., 2011-01-19: Peer-reviewed projection linking SEER prevalence to SEER-Medicare costs: $124.57B in 2010 and $157.77B in 2020 if incidence, survival and costs stay constant, rising to $173B with 2% annual cost growth. Funders: NCI authors (Surveillance Research Program); no industry funding or competing interest declared in the PubMed record. No drug or maker. Comparator: three cost-trend scenarios. The $207.9B upper figure sits in the full text's 5% scenario and is rounded to $207B by NCI (CHE-01). Free full text PMC3107566.
